Weight-Loss Treatment When Your BMI Is 35 or Higher

If your BMI is 35 or higher, you have almost certainly been told to "just eat less and move more" more times than you can count. You have probably done it, too, often losing weight and then watching it creep back despite doing everything right. That pattern is not a failure of willpower. At a higher BMI, your body actively defends its weight through hunger hormones and a metabolism that adapts to hold on to fat, which is precisely why lifestyle change alone works for so few people at this end of the scale.

The good news is that there are now genuinely effective, prescription-only medical options, and a BMI of 35 sits comfortably within the range where treatment is licensed. This guide explains what those options are, who is eligible, how much weight people actually lose in the clinical trials, what the real risks are, and how to start safely with a UK pharmacy rather than an unregulated seller.

Does a BMI of 35+ change what treatment I can access?

Yes, and mostly in your favour. Body Mass Index is a screening tool, not a diagnosis. It divides your weight in kilograms by your height in metres squared, and while it says nothing about muscle, body shape or where you carry fat, it remains the standard threshold the UK uses to decide who is eligible for weight-loss medication.

The licensed medicines used for weight loss in the UK, tirzepatide (Mounjaro) and semaglutide (Wegovy), are approved by the Medicines and Healthcare products Regulatory Agency for adults with a BMI of 30 or above, or 27 or above if you also have a weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. Source: electronic Medicines Compendium — Mounjaro SmPC.

A BMI of 35 is therefore already well inside the range where these treatments are appropriate. It also usually sits above the point where doctors start to see weight-related conditions clustering together, which is part of why treatment tends to be prioritised for people in this group. If your background is South Asian, Chinese, Middle Eastern, Black African or African-Caribbean, be aware that the risk from excess weight tends to appear at a lower BMI, so the relevant thresholds are often set lower for you too. Source: NICE — Obesity: identification, assessment and management.

One thing worth clearing up early: the private BMI threshold above is not the same as the much stricter cut-offs the NHS uses to decide who it will fund. Those NHS criteria are about limited budgets and rollout phases, not about whether the medicine can safely and legally be prescribed to you. You can read more in our guide to who qualifies for weight-loss medication by BMI.

Why is losing weight so much harder at a higher BMI?

Because your body treats your current weight as the level it needs to protect. When you diet, several hormones shift against you. Leptin, which should tell your brain you have enough fat stored, becomes less effective, so the "you're full, stop eating" message weakens. Ghrelin, the hormone that drives hunger, stays elevated. And your resting metabolic rate tends to fall as you lose weight, so your body burns fewer calories than before even at the same size. The result is relentless hunger and a slowing engine, which is exactly the combination that makes weight regain so common.

This is where the modern medicines come in. Tirzepatide and semaglutide are based on gut hormones your body produces naturally after eating. Semaglutide mimics GLP-1 (glucagon-like peptide-1); tirzepatide mimics both GLP-1 and a second hormone, GIP. Both slow how quickly your stomach empties and dampen appetite signals in the brain, so you feel satisfied with less food and the constant food noise quietens. They do not override biology so much as restore a signal that was not landing properly. That is why they are a tool for a physiological problem, not a shortcut, and why they work best alongside changes to what and how you eat.

Mounjaro or Wegovy: what does the evidence show?

Both are prescription-only injectable medicines, given once a week, and both are started at a low dose that is increased gradually to reduce side effects. The main practical difference is how much weight people tend to lose in the trials and how the dose is stepped up.

The headline figures come from named clinical trials. In SURMOUNT-1, adults taking the highest 15 mg dose of tirzepatide lost about 22.5% of their body weight over 72 weeks. Source: SURMOUNT-1, New England Journal of Medicine. In STEP 1, adults taking 2.4 mg of semaglutide lost about 14.9% of their body weight over 68 weeks. Source: STEP 1, New England Journal of Medicine.

Two honest caveats. First, these are trial averages achieved alongside structured diet and activity support, and individual results vary considerably; some people lose more, some less. Second, a bigger number on paper does not automatically make one medicine "right" for you. The best choice depends on your medical history, how you tolerate the treatment, cost and how your body responds. Many people at a higher BMI start with Mounjaro for its greater average effect, but that is a clinical decision to make with a prescriber, not a foregone conclusion. You can compare them in more depth on our Mounjaro and Wegovy pages, and there is now also an oral option covered on our Wegovy Tablet page.

What are the risks and side effects?

The most common side effects of both medicines are gastrointestinal: nausea, diarrhoea, constipation and occasionally vomiting, especially in the first weeks and after each dose increase. These are usually mild to moderate and tend to settle as your body adjusts, which is exactly why the dose is raised slowly rather than started high.

There are rarer but more serious risks you should know about before starting. These include inflammation of the pancreas (pancreatitis) and gallbladder problems such as gallstones, both of which need prompt medical attention. These medicines are not suitable for everyone. Key contraindications and cautions include a personal or family history of medullary thyroid cancer or the condition MEN 2, a previous episode of pancreatitis, pregnancy or breastfeeding, and certain gastrointestinal conditions. A proper consultation exists to catch these before a prescription is ever issued. General safety information is published by the regulator via the electronic Medicines Compendium.

If you do experience a side effect, you can report it directly through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps the Agency monitor the safety of medicines in real-world use, and it works alongside, not instead of, telling your prescriber.

A word on where you buy these medicines. Tirzepatide and semaglutide are prescription-only and can be supplied lawfully only after an online consultation and clinical assessment by a prescriber. Any website, social media account or messaging seller offering "weight-loss jabs" without a prescription is operating illegally, and the products are frequently counterfeit and genuinely dangerous. A legitimate UK pharmacy will be registered with the General Pharmaceutical Council and will never sell you these medicines without assessing your suitability first.

NHS or private: which route fits a high BMI?

You have two legitimate routes, and they are not in competition so much as suited to different situations.

The NHS does prescribe these medicines, but access is tightly rationed through phased eligibility criteria and specialist weight-management services, and waiting times can be long. Its cut-offs are stricter than the MHRA licence because they are about funding capacity, not clinical safety. For many people at a BMI of 35, the NHS route is a real option worth exploring with your GP, particularly if you have several weight-related conditions.

A regulated private pharmacy offers a faster, parallel path for people who meet the clinical criteria but do not want to wait, or who do not qualify under the narrower NHS funding rules despite being eligible for treatment under the licence. This is not "queue-jumping"; it is a separate, self-funded service governed by the same medicines law and the same pharmacy regulation. Whichever route you choose, the safety standard is identical: a genuine clinical assessment, a prescriber's decision, and a GPhC-registered pharmacy dispensing the medicine. The main practical trade-off is speed and choice on one side, versus cost on the other, and there is no wrong answer, only the one that fits your circumstances. If you decide the private route suits you, a free eligibility check is the quickest way to find out where you stand, and it commits you to nothing.

How it works at The Weight Clinic

The Weight Clinic is a UK online pharmacy registered with the General Pharmaceutical Council. Care is overseen by our Superintendent Pharmacist, Andrew Lane, with prescribing led by Pharmacist Independent Prescriber Fatma Al Sibahi and clinical content reviewed by Pharmacist Independent Prescriber Ali Al Sibahi.

The process is deliberately straightforward. You complete a free online eligibility check and a detailed medical questionnaire covering your history, current medicines and any conditions. A prescriber reviews your case individually, and if a treatment is clinically appropriate, it is dispensed from our pharmacy and delivered discreetly, with ongoing support as you titrate the dose. If a treatment is not safe or suitable for you, we will tell you plainly rather than issue it anyway.

On cost, Mounjaro starts from £125 a month and Wegovy costs from £80 for your first month (£115 standard, with £35 off your first order using code NEWME). There is no subscription and no long waiting list. If you would like to know where you stand, the simplest first step is to check your eligibility. It takes a few minutes and commits you to nothing.

You may also find it useful to browse all of our weight-loss injections or the full range of treatments we offer.

The takeaway

A BMI of 35 or above is a medical situation, not a personal shortcoming, and it is one that modern, licensed treatments are designed to help with. Mounjaro and Wegovy work by correcting appetite and satiety signals that a higher BMI disrupts, and the trial evidence for both is strong, though results vary from person to person. They are prescription-only medicines with real, if usually manageable, side effects, so the safe path always runs through a proper clinical assessment and a registered pharmacy. If that sounds like the kind of support you have been missing, a free eligibility check is a low-stakes place to begin.